Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. We are blending butter pecan and pumpkin spice today, since we enjoy early-stage scientific experiments. Feel free to indulge your own caffeine fantasies as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day and, as always, do drop us a line when you hear something interesting.

A former Takeda Pharmaceuticals (TKPYY) chairman is voicing opposition to the proposed $62 billion acquisition of Shire (SHPG), breaking a long silence, The Nikkei Asian Review reports. Mergers and acquisitions are necessary in the pharmaceutical industry, “but the Shire deal’s risk is high,” says Kunio Takeda. His comments come ahead of a Dec. 5 shareholder meeting to approve the deal. Takeda, 78, held leadership positions with the company such as president and chairman from 1993 to 2009, overseeing a period of fast growth.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy